| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Evercore ISI Group analyst Elizabeth Anderson maintains Health Catalyst (NASDAQ:HCAT) with a In-Line and lowers the price ta...
 
																	Keybanc analyst Scott Schoenhaus maintains Health Catalyst (NASDAQ:HCAT) with a Overweight and lowers the price target from ...
 
																	Cantor Fitzgerald analyst Sarah James reiterates Health Catalyst (NASDAQ:HCAT) with a Neutral and maintains $4 price target.
 
																	 
																	 
																	BTIG analyst David Larsen reiterates Health Catalyst (NASDAQ:HCAT) from Neutral to Neutral.
 
																	Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ:HCAT) with a Buy and lowers the price target from ...
 
																	Evercore ISI Group analyst Elizabeth Anderson maintains Health Catalyst (NASDAQ:HCAT) with a In-Line and raises the price ta...
